

STALLERGENES GREER

advancing allergy care

to be closer to the needs of every patient



A fully integrated global biopharmaceutical company

More than 150 years combined experience in allergy innovation
A strong & comprehensive portfolio of state-of-the-art allergy immunotherapy (AIT) treatments, covering all administration routes, plus diagnostic products




Commitment and expertise to bring AIT to the **highest quality standards**

Largest manufacturing capacity globally for allergens and finished AIT products

A major player in the global AIT market, owning **28% worldwide MS***

A diversified global footprint

A direct presence in **22** countries
 Treatments available in **75** countries
 Manufacturing facilities in **Europe** and the **Americas**




Worldwide **1.6 million** patients treated annually
1,400 employees

● R&D centers
 ● Technical operations

Enabling people with allergies to live a normal life

Innovative capacity to develop next generation products & technologies



* In 2015
 † On unaudited pro forma basis